UMC, the Dutch research firm that has been at the center of the regional epidemic controversy in the Middle East has applied for a patent for the disease and its vaccine, offering access to countries at a “fair market price.”
The group brought into Turkey to research a flu-like illness that was killing people in Turkish refugee camps on the Syrian border. After it conducted some research and refused to share the results with the Turkish government, Turkey said that it had expelled the for-profit entity, which quickly aligned itself with Syria and gained access to Syrian patients of the disease.
“We have patented the rights to the vaccine of the disease according to international standards and are glad to sell the rights to use the vaccine to affected citizens,” UMC said in a release.
Now, UMC, with its patent filed, is denouncing Syria and leaving that country.
“We would also like to announce our immediate and complete withdrawal from Syrian territory. The alliance between the UMC and the Syrian government was based solely on scientific research and thanks to our discovery this alliance holds no further purpose. Frankly, we find the sadistic pleasure with which the Assad regime ruthlessly murders his own people utterly deplorable and support the international community’s effort for regime transition Syria.”